ClinicalTrials.gg
Active, not recruitingNCT07048548Updated Jul 2, 2025

Assessment of THL and Potential Risk of Hypothyroidism in Healthcare Workers Exposed to Low-dose Ionizing Radiation

An observational study in Hyperthyroidism, sponsored by Superior University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Superior University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
44
Ages
20 Years to 40 Years
Sex
All
01

Study summary

"This study is designed to evaluate the thyroid health of healthcare workers exposed to low-dose ionizing radiation at INMOL Cancer Hospital, Lahore. Specifically, it investigates whether prolonged occupational exposure in radiology and nuclear medicine departments is associated with altered thyroid hormone levels or an increased risk of hypothyroidism. The thyroid gland is highly sensitive to radiation, and existing literature suggests a possible link between occupational exposure and thyroid dysfunction.

Read the detailed description

A cross-sectional research design will be used over a four-month period. A sample of 44 participants will be selected using purposive sampling from the hospital's radiology and nuclear medicine staff.

02

Conditions studied

  • Hyperthyroidism

Browse trials for

03

In context

Hyperthyroidism

112 studies on the registry are indexed under Hyperthyroidism; 27 are open to participants now.

This study's enrollment of 44 is below the median of 98 across 48 observational studies indexed under Hyperthyroidism.

Browse Hyperthyroidism studies →

Lead sponsor

Superior University is the lead sponsor of 253 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This study will include healthcare professionals from the radiology and nuclear medicine departments at INMOL Cancer Hospital with at least one year of radiation exposure. A total of 44 participants will be selected through purposive sampling.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Staff members from radiology and nuclear medicine departments who meet both conditions.
  • workplace experience exceeding one year
  • age between 20 to 40 will be selected for this study.

Exclusion criteria

Exclusion Criteria:

  • Employees who have worked less than twelve months
  • pregnant participants.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
44 participants (actual)
Patient registry
No

Groups and cohorts

  • Thyroid Function Monitoring

    Behavioral: Thyroid Function Monitoring

Interventions

  • BehavioralThyroid Function Monitoring

    This study will include healthcare professionals from the radiology and nuclear medicine departments at INMOL Cancer Hospital with at least one year of radiation exposure. A total of 44 participants will be selected through purposive sampling. Data will be collected using a structured questionnaire and blood tests for thyroid hormones (TSH, T3, T4) to assess thyroid function. Blood analysis will be conducted using CLIA or ELISA methods. The aim is to detect any association between low-dose radiation exposure and thyroid dysfunction.

06

What researchers measure

Primary outcomes

  1. thyroid function assessment

    Thyroid function is assessed through blood tests, primarily measuring TSH (Thyroid Stimulating Hormone), T4 (Thyroxine), and sometimes T3 (Triiodothyronine) levels. Abnormal levels of these hormones can indicate an underactive (hypothyroidism) or overactive (hyperthyroidism) thyroid. Normal Ranges (approximate): TSH: 0.4 - 4.0 mIU/L Free T4: 0.7 - 1.9 ng/dL Total T4: 5.0 - 12.0 μg/dL Total T3: 80 - 220 ng/dL

    Time frame: 12 Months

07

Study locations

1 site
  • INMOL hospital
    Lahore, Punjab Province, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Jun 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 2, 2025
StartActual
Mar 18, 2025
Primary completionActual
Jun 20, 2025
CompletionEst.
Feb 1, 2026
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07048548
Responsible party
Muhammad Naveed Babur (Principal Investigator, Superior University) — Principal investigator
First posted
Jul 2, 2025
Start date
Mar 18, 2025
Primary completion
Jun 20, 2025
Completion
Feb 1, 2026 (estimated)
Last update
Jul 2, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion